Examination of Trends in Colorectal Cancer Patients' Clinical Study Experiences

A Detailed Exploration of The Perspectives and Experiences of Patients in Colorectal Cancer Clinical Trials

Clinical study participation percentages haven't always been fully representative of a given demographic.

Participation in this observational clinical research is extremely valuable since it allows people with colorectal cancer to contribute their own experiences and unique viewpoints.

These vital contributions have the potential to affect the development of novel therapies and support services dramatically.

Trial's findings will be critical in furthering the understanding of colorectal cancer, ultimately leading to better patient outcomes.

Study Overview

• Status: Not yet recruiting
• Conditions: Colorectal Cancer

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Michael B Gill; Phone Number: 415-900-4227; Email: bask@withpower.com

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94107
      • Power Life Sciences
      • Contact: Michael B Gill; Phone Number: 415-900-4227; Email: https://www.withpower.com/contact-us@withpower.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Colorectal cancer patients who are actively considering involvement in an observational clinical study, but have not yet completed enrollment and registration.

Description

Inclusion Criteria:

• Participant has a diagnosis of colorectal cancer
• Patient has self-identified as planning to enroll in a clinical trial for colorectal cancer
• Patient is at least 18 years of age

Exclusion Criteria:

• Inability to perform regular electronic reporting
• Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial
• Pregnant or lactating woman

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Rate of patients who decide to enroll in a colorectal cancer clinical study.	3 months
Number of colorectal cancer patients who remain in clinical trial until completion.	12 months

Collaborators and Investigators

• Sponsor: Power Life Sciences Inc.
• Investigators: Study Director: Michael B Gill, Power Life Sciences Inc.

Publications and helpful links

General Publications

• Winkels RM, Heine-Broring RC, van Zutphen M, van Harten-Gerritsen S, Kok DE, van Duijnhoven FJ, Kampman E. The COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer. 2014 May 27;14:374. doi: 10.1186/1471-2407-14-374.
• Veettil SK, Wong TY, Loo YS, Playdon MC, Lai NM, Giovannucci EL, Chaiyakunapruk N. Role of Diet in Colorectal Cancer Incidence: Umbrella Review of Meta-analyses of Prospective Observational Studies. JAMA Netw Open. 2021 Feb 1;4(2):e2037341. doi: 10.1001/jamanetworkopen.2020.37341.
• Njor SH, Andersen B, Friis-Hansen L, de Haas N, Linnemann D, Norgaard H, Roikjaer O, Sondergaard B, Rasmussen M. The optimal cut-off value in fit-based colorectal cancer screening: An observational study. Cancer Med. 2021 Mar;10(5):1872-1879. doi: 10.1002/cam4.3761. Epub 2021 Feb 3.

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2024
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): June 1, 2024

Study Registration Dates

• First Submitted: May 26, 2023
• First Submitted That Met QC Criteria: May 26, 2023
• First Posted (Actual): June 7, 2023

Study Record Updates

• Last Update Posted (Actual): June 7, 2023
• Last Update Submitted That Met QC Criteria: May 26, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: colorectal cancer
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: 82251637

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No